A phase III randomized study of misonidazole plus radiation vs. radiation alone for cervix cancer

Radiotherapy and Oncology

Volumn 70, Issue 3, 2004, Pages 295-299

  Chan, Philip ^a   Milosevic, Michael ^a,c   Fyles, Anthony ^a,c   Carson, John ^b   Pintilie, Melania ^a   Rauth, Michael ^a,c   Thomas, Gillian ^c  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b Department of Radiation Oncology   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Cervix cancer; Hypoxia; Radiotherapy; Randomized trial

Indexed keywords

MISONIDAZOLE; PLACEBO;

ADOLESCENT; ARTICLE; BRACHYTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG SCREENING; FEMALE; HEALTH CENTER; HOSPITAL; HUMAN; MAJOR CLINICAL STUDY; OUTCOMES RESEARCH; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; SURVIVAL TIME; TIME; TREATMENT FAILURE; UTERINE CERVIX CANCER;

ADENOCARCINOMA; CARCINOMA, SQUAMOUS CELL; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MISONIDAZOLE; RADIATION-SENSITIZING AGENTS; RADIOTHERAPY DOSAGE; SURVIVAL RATE; UTERINE CERVICAL NEOPLASMS;

EID: 1942439101     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.radonc.2003.11.018     Document Type: Article

References (33)

1. The Medical Research Council trial of misonidazole in carcinoma of the uterine cervix. A report from the MRC working party on misonidazole for cancer of the cervix. Br J Radiol 1984; 57; 491-9.
2. A trial of Ro 03-8799 (pimonidazole) in carcinoma of the uterine cervix: an interim report from the Medical Research Council Working Party on advanced carcinoma of the cervix. Radiother Oncol 1993; 26: 93-103.
3. Beran M., Tribukait B. Haemopoietic aspects of the changes in the natural radiation resistance of mice after hypoxia. Acta Radiol Ther Phys Biol. 11:1972;225-239.
4. Bolger B.S., Dabbas M., Lopes A., Monaghan J.M. Prognostic value of preoperative squamous cell carcinoma antigen level in patients surgically treated for cervical carcinoma. Gynecol Oncol. 65:1997;309-313.
5. Bush R.S., Jenkin R.D., Allt W.E., et al. Definitive evidence for hypoxic cells influencing cure in cancer therapy. Br J Cancer Suppl. 37:1978;302-306.
6. Coleman C.N., Noll L., Riese N., et al. Final report of the phase I trial of continuous infusion etanidazole (SR 2508): a radiation therapy oncology group study. Int J Radiat Oncol Biol Phys. 22:1992;577-580.
7. Elkind M.M. Fundamental questions in the combined use of radiation and chemicals in the treatment of cancer. Int J Radiat Oncol Biol Phys. 5:1979;1711-1720.
8. Fowler J.F. Eighth Annual Juan del Regato Lecture. Chemical modifiers of radiosensitivity - theory and reality: a review. Int J Radiat Oncol Biol Phys. 11:1985;665-674.
9. Fyles A., Milosevic M., Hedley D., et al. Tumour hypoxia has independent predictor impact only in patients with node-negative cervix cancer. J Clin Oncol. 20:2002;680-687.
10. Fyles A.W., Milosevic M., Wong R., et al. Oxygenation predicts radiation response and survival in patients with cervix cancer. Radiother Oncol. 48:1998;149-156.
11. Fyles A.W., Pintilie M., Kirkbride P., Levin W., Manchul L.A., Rawlings G.A. Prognostic factors in patients with cervix cancer treated by radiation therapy: results of a multiple regression analysis. Radiother Oncol. 35:1995;107-117.
12. Gambino J.J., Lindberg R.G., Hayden P. A search for mechanisms of radiation resistance in pocket mice. Radiat Res. 26:1965;305-317.
13. Gatzemeier U., Rodriguez G., Treat J., et al. Tirapazamine-cisplatin: the synergy. Br J Cancer. 77:(Suppl 4):1998;15-17.
14. Girinski T., Pejovic M.H., Haie C., et al. Radical irradiation and misonidazole in the treatment of advanced cervical carcinoma: results of a phase II trial. Int J Radiat Oncol Biol Phys. 11:1985;1783-1787.
15. Grigsby P.W., Winter K., Wasserman T.H., et al. Irradiation with or without misonidazole for patients with stages IIIB and IVA carcinoma of the cervix: final results of RTOG 80-05. Radiation therapy oncology group. Int J Radiat Oncol Biol Phys. 44:1999;513-517.
16. Hill S.A., Collingridge D.R., Vojnovic B., Chaplin D.J. Tumour radiosensitization by high-oxygen-content gases: influence of the carbon dioxide content of the inspired gas on PO2, microcirculatory function and radiosensitivity. Int J Radiat Oncol Biol Phys. 40:1998;943-951.
17. Howe L.R., Subbaramaiah K., Patel J., et al. Celecoxib, a selective cyclooxygenase 2 inhibitor, protects against human epidermal growth factor receptor 2 (HER-2)/neu-induced breast cancer. Cancer Res. 62:2002;5405-5407.
18. Kaanders J.H., Bussink J., van der Kogel A.J. ARCON: a novel biology-based approach in radiotherapy. Lancet Oncol. 3:2002;728-737.
19. Kalbfleisch J.D., Prentice R.L. The statistical analysis of failure time data. 1980;Wiley, New York.
20. 2-measurements as predictive assay in the treatment of carcinoma of the uterine cervix. Radiother Oncol. 53:1999;99-104.
21. Masunaga S., Ono K., Nishimura Y., et al. Combined effects of tirapazamine and mild hyperthermia on anti-angiogenic agent (TNP-470) treated tumours-reference to the effect on intratumour quiescent cells. Int J Radiat Oncol Biol Phys. 47:2000;799-807.
22. Overgaard J. Clinical evaluation of nitroimidazoles as modifiers of hypoxia in solid tumours. Oncol Res. 6:1994;509-518.
23. Overgaard J., Bentzen S.M., Kolstad P., et al. Misonidazole combined with radiotherapy in the treatment of carcinoma of the uterine cervix. Int J Radiat Oncol Biol Phys. 16:1989;1069-1072.
24. Pitson G., Fyles A., Milosevic M., Wylie J., Pintilie M., Hill R. Tumour size and oxygenation are independent predictors of nodal diseases in patients with cervix cancer. Int J Radiat Oncol Biol Phys. 51:2001;699-703.
25. Rijpkema M., Kaanders J.H., Joosten F.B., van der Kogel A.J., Heerschap A. Effects of breathing a hyperoxic hypercapnic gas mixture on blood oxygenation and vascularity of head-and-neck tumours as measured by magnetic resonance imaging. Int J Radiat Oncol Biol Phys. 53:2002;1185-1191.
26. Rizzo J.D., Lichtin A.E., Woolf S.H., et al. Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American society of clinical oncology and the American society of hematology. J Clin Oncol. 20:2002;4083-4107.
27. Stehman F.B., Bundy B.N., Thomas G., et al. Hydroxyurea versus misonidazole with radiation in cervical carcinoma: long-term follow-up of a gynecologic oncology group trial. J Clin Oncol. 11:1993;1523-1528.
28. Thomas G.M., Rauth A.M., Black B.E., Cummings B.J., Sorenti V.L., Bush R.S. A phase I study of misonidazole and pelvic irradiation in patients with carcinoma of cervix. Br J Cancer. 45:1982;860-868.
29. Urtasun R.C., Coleman C.N., Wasserman T.H., Phillips T.L. Clinical trials with hypoxic cell sensitizers: time to retrench or time to push forward? Int J Radiat Oncol Biol Phys. 10:1984;1691-1696.
30. Wang Z., Fuentes C.F., Shapshay S.M. Antiangiogenic and chemopreventive activities of celecoxib in oral carcinoma cell. Laryngoscope. 112:2002;839-843.
31. Wong R.K., Fyles A., Milosevic M., Pintilie M., Hill R.P. Heterogeneity of polarographic oxygen tension measurements in cervix cancer: an evaluation of within and between tumour variability, probe position, and track depth. Int J Radiat Oncol Biol Phys. 39:1997;405-412.
32. Workman P., Stratford I.J. The experimental development of bioreductive drugs and their role in cancer therapy. Cancer Metastasis Rev. 12:1993;73-82.
33. Yasuda Y., Fujita Y., Masuda S., et al. Erythropoietin is involved in growth and angiogenesis in malignant tumours of female reproductive organs. Carcinogenesis. 23:2002;1797-1805.